Analysis for AMGN

📈 Growth & Financial Trajectory

From 2024 Q1 to 2026 Q1, AMGN shows a modest revenue rise from about $7.447B to $8.618B and a turn from a small quarterly net loss (-$0.113B) to positive net income of about $1.819B. The eight-quarter trend is broadly upward, with net income and gross profit expanding across periods and operating income remaining robust. Revenue growth is steady rather than explosive, reflecting a durable base business and favorable pricing/mix. A late-2025 dip in cash flow gave way to a rebound in 2026 Q1.

💰 Margins & Cash Flow

Gross margin stayed robust, with gross profit margins commonly in the high 60s to low 80s (peaking above 80% in some 2024 periods). Operating margins tracked this strength, aided by disciplined SG&A as revenues climbed. Net cash flow from operating activities was mostly positive, peaking around $3.57B in 2024 Q3, with positives through 2025 milestones and a temporary net cash outflow in 2025 Q4 before a rebound in 2026 Q1. Overall cash flow supported a solid balance sheet, despite financing activities showing some variability.

🛡️ Balance Sheet & Liquidity

AMGN carries a large asset base (around $90B+) and a long-term debt load typically near $60B. Current assets ($27–31B) exceed current liabilities ($20–21B), implying positive working capital. Equity remains modest relative to liabilities, but liquidity and gross earnings support resilience.

⚠️ Key Drivers & Risks

• Drivers: Robust biologics demand and favorable pricing/mix in core franchises
• Risks: Revenue/pipeline cyclicality and debt/currency/regulatory sensitivity